Inositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With PCOS
Eligible age
20–40 yrs
Accepts
Women
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Polycystic ovary syndrome (PCOS) is a common endocrine disorder frequently associated with obesity, insulin resistance (IR), and metabolic dysfunction. Although lifestyle modification is recommended as first-line therapy, the optimal dietary approach for women with PCOS remains uncertain. This randomized, controlled, open-label, parallel-group trial aims to compare the effects of a Mediterranean diet (MD) and a low-carbohydrate diet (LCD), each combined with metformin, inositol, or folic acid (active control), in obese women with PCOS and IR. A total of 102 participants will be randomly assigned to one of six intervention groups and followed for two months. Anthropometric measurements, body composition, biochemical parameters, and hedonic hunger will be assessed at baseline and after the intervention. The primary outcome is the change in insulin resistance, assessed by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), from baseline to 2 months. Secondary outcomes include changes in body composition, metabolic and biochemical parameters, and hedonic hunger.
Sponsor: Dicle University
You may qualify if…
- ✓ Women aged 20-40
- ✓ Diagnosed with PCOS (Rotterdam, 2004)
- ✓ Insulin resistant (newly diagnosed or diagnosed within the last 3 months)
- ✓ Obese according to the World Health Organization (2006) in grades 1 and 2 (BMI: 30-40 kg/m²)
You may not qualify if…
- ✕ Pregnant or breastfeeding women
- ✕ Those undergoing/contemplating IVF treatment
- ✕ Early menopause diagnosis
- ✕ Diabetes diagnosis, use of oral antidiabetic agents
- ✕ Chronic diseases (liver, kidney diseases, cancer)
- ✕ Psychiatric illnesses
- ✕ Those taking routine medication for any reason
- ✕ Use of hormonal contraceptive methods within the last 3 months
Source: ClinicalTrials.gov · NCT07770711 · last updated 2026-10-16